Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

Sponsor
University of California, San Diego
Study ID
NCT07255781
Status
Withdrawn

Conditions

  • NAFLD (Nonalcoholic Fatty Liver Disease)
  • PsA (Psoriatic Arthritis)
  • Psoriasis (PsO)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Guselkumab Prefilled Syringe [Tremfya] — DRUG
    This trial aims to recruit patients who have psoriatic disease, have evidence of fatty liver disease, and have a BMI over 25, who are planning to start Guselkumab(Tremfya) as recommended by their primary rheumatologist or dermatologist

Study Details

The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved by the FDA instead of the standard of care to treat PD), for NAFLD patients who receive Guselkumab for their PD.

Key Dates

Start date
Nov 30, 2025
Status verified
Feb 2026
Primary completion
Nov 30, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
0 participants (actual)

Arms

  • Arm: Active Psoriatic Disease
    Patients with active psoriatic disease (diagnosed with psoriasis and/or psoriatic arthritis) who are planning to start Guselkumab as part of their standard of care.

Primary Outcome Measure

Improvement in NAFLD severity [ Time Frame: 6 months ]

Related Studies